Last Updated: June 2, 2026

Patent: 8,435,518


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,435,518
Title:Methods of using IL-17 receptor a antibodies
Abstract:The present invention relates to IL-17 Receptor A antigen binding proteins, such as antibodies, and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation.
Inventor(s):Tocker Joel, Peschon Jacques J., Fitzpatrick David
Assignee:Kirin-Amgen, Inc.
Application Number:US12899290
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

United States Patent 8,435,518: Claims, Scope, and U.S. Patent Landscape Fit

What does US 8,435,518 claim, and what is the enforceable scope?

No claim text was provided after “The claims are:”. Without the actual claim language, the enforceable scope cannot be derived, claim elements cannot be construed, and infringement/validity risk cannot be mapped to the prior-art landscape.

What is the patent-family position, priority chain, and remaining U.S. life?

Insufficient information was provided to identify the full patent family, priority dates, continuations/divisionals, and U.S. term adjustments. Without those data, it is not possible to calculate expiration timing, bench the prosecution history, or assess whether later family members narrow or broaden claim scope.

How does US 8,435,518 map to known prior art and design-around options?

A prior-art and design-around analysis requires: (1) claim elements, (2) earliest effective filing date(s), (3) technology area/assignee-specific focus, and (4) the published literature and patent citations used in prosecution. None of those inputs were included with the request, so a critical landscape mapping cannot be produced.

Where are litigation hotspots likely in the U.S.?

Hotspots depend on: claim breadth, functional language, compositions versus methods, standard-of-care claims, and the presence of close competitor patents in the same claim space. These determinations require the claim text and prosecution record. No claim text was provided.

What is the actionable U.S. competitor and citation landscape around the same claim space?

Competitor mapping requires at minimum the assignee, CPC/US classifications, and claim-specific technology keywords. None of those were provided. Without them, any competitor or citation landscape would be speculative.


Key Takeaways

  • US 8,435,518 cannot be critically analyzed for claim scope, validity, infringement risk, or landscape competition without the actual claim text and related bibliographic inputs (family/priority/assignee/technology classification).
  • No authoritative prior-art or competitor mapping can be performed from the patent number alone under the constraints of a non-speculative patent analysis.

FAQs

  1. Can a claim-by-claim scope analysis be completed without the claim language?
    No. Claim construction is element-driven and requires the exact claim text.

  2. Can the patent’s remaining U.S. enforceable term be calculated without priority and term-adjustment data?
    No. Expiration depends on priority chain and any PTA/PTD and publication/filing details.

  3. Can a prior-art landscape be built without knowing the technology and claim elements?
    No. Prior-art mapping requires claim-specific constraints and classification keywords.

  4. Can potential design-arounds be identified without knowing functional claim boundaries?
    No. Design-arounds hinge on what the claims actually require.

  5. Can litigation likelihood be assessed without scope and prosecution context?
    No. Hotspots depend on how the claims were narrowed or argued during prosecution.


References

[1] USPTO Patent Center. United States Patent 8,435,518 (Bibliographic record). https://patentscope.uspto.gov/
[2] USPTO Patent Public Search. US 8,435,518 (Full text and claims). https://ppubs.uspto.gov/

More… ↓

⤷  Start Trial

Details for Patent 8,435,518

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Valeant Pharmaceuticals Luxembourg S.à.r.l. SILIQ brodalumab Injection 761032 February 15, 2017 ⤷  Start Trial 2030-10-06
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.